Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...

Complement 3 glomerulopathy (C3G) is considered a very rare disease. With C3G, patients have issues with their immune system that cause kidney damage and symptoms such as swelling and changes in urine ...

C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) are two rare kidney diseases. They’re both driven by activity of the complement system, which is a ...

The complement system is a key component of innate and adaptive immunity and therefore acts as a vital defense against invading pathogens. Deficiencies in the complement system are associated with ...

Researchers have discovered that SARS-CoV-2 hijacks three important host proteins that dampen the activity of the complement system, a key component of early antiviral immunity. This significantly ...

K. pneumoniae is frequently the source of hospital-acquired infections and, due to the widespread use of antibiotics in these settings, has also acquired numerous resistance genes. In fact, over ...

Complement 3 glomerulopathy (C3G) is a rare kidney disease caused by problems in the body's complement system, which normally helps fight infections. It damages tiny filters in your kidneys called ...

Journal in the field and provides all-inclusive access to the critical pillars of human gene therapy: research, methods, and clinical applications. Recent clinical trials utilizing high doses of adeno ...

Current treatment methods for C3 glomerulopathy (C3G) help support kidney function and suppress immune system activity. Emerging therapies interrupt the proteins responsible for disease activity. C3G ...